Editor's Choice: Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding Editorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practice Hosted by: Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USA Featuring: Jamie N. Bakkum-Gamez, MD; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA John B. Kisiel, MD; Division...

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review Moderator: Ursula A. Matulonis, MD; Dana-Farber Cancer Institute Speakers: Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone Health Róisín E. O’Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical College Yvett...

Editor's Choice: Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer Editorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection Hosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada Featuring: Surabhi Tewari, MD, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USA Alexander Melamed, MD...

Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement Hosted by: Jose Alejandro Rauh-Hain, MD MPH Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Featuring: Charles A. Powell, MD, MBA Division of Pulmonary, Critical Care and Sleep Medicine, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA Check out more...

Editor's Choice: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial Editorial: Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup Canadian Cance...

Editor’s Choice: Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment? Editorial: Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: Rebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USA Christina M. Annunziata, American Cancer Society, Atlanta, GA, USA Check out more content on the ...

Editor’s Choice: Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approaches Editorial: Who is following up? Rethinking survivorship and surveillance Hosted by: Paola A Gehrig, MD University of Virginia Charlottesville, Virginia United States Featuring: Lee-may Chen, MD; Division of Gynecologic Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States Esther Vermaas; Department of Obstetrics and Gynaecology,...

Editor’s Choice: Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant Editorial: Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 carriers:Why is this a question? Hosted by: John Farley, MD, COL(ret), FACOG, FACS, St Joseph's Hospital and Medical Center, Phoenix, AZ, United States of America Featuring: Steven Narod, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada Stephanie Blank, Icahn School of Medic...

Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer Editor’s Choice: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer Editorial: From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncology Hosted by:...

Editor’s Choice: Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: William Cliby, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA Chiara Ainio, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA Oliver Zivanovic, Clinic for Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, German...